CalciMedica (NASDAQ:CALC) Issues Quarterly Earnings Results, Misses Expectations By $0.12 EPS

CalciMedica (NASDAQ:CALC) released its quarterly earnings results on Tuesday. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.12), Zacks reports.

CalciMedica Trading Up 1.4%

NASDAQ CALC traded up $0.01 on Tuesday, hitting $0.67. 54,483 shares of the company’s stock were exchanged, compared to its average volume of 1,074,717. The stock has a 50-day moving average of $0.83 and a 200-day moving average of $0.88. The stock has a market cap of $10.55 million, a price-to-earnings ratio of -0.51 and a beta of 0.91. CalciMedica has a 52 week low of $0.46 and a 52 week high of $7.20.

Insider Activity

In other CalciMedica news, Director Fred A. Middleton purchased 248,972 shares of the stock in a transaction dated Thursday, June 25th. The stock was bought at an average price of $0.80 per share, with a total value of $199,177.60. Following the acquisition, the director owned 1,063,272 shares of the company’s stock, valued at approximately $850,617.60. This represents a 30.57% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 28.25% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Boothbay Fund Management LLC acquired a new position in CalciMedica during the fourth quarter worth about $506,000. Envestnet Asset Management Inc. grew its holdings in shares of CalciMedica by 58.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after purchasing an additional 34,386 shares during the last quarter. Jane Street Group LLC acquired a new position in CalciMedica during the 4th quarter worth approximately $127,000. Renaissance Technologies LLC lifted its stake in CalciMedica by 26.1% in the 4th quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock valued at $582,000 after purchasing an additional 18,300 shares during the last quarter. Finally, Cetera Investment Advisers lifted its stake in CalciMedica by 33.1% in the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after purchasing an additional 9,045 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on CALC shares. HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. Weiss Ratings upgraded shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $10.00.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.